Paul Jones, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6822 East / 1000 South, Fort Duchesne, UT 84026 Phone: 435-725-6858 Fax: 435-722-9137 |
News Archive
Recognizing that venous interventions may potentially play an important role in treating some patients who suffer from multiple sclerosis an incurable, disabling disease the Society of Interventional Radiology has issued a position statement indicating its support for high quality clinical research to determine the safety and effectiveness of interventional M.S. treatments.
Few doctors think of themselves as rich, and only about half think they're fairly compensated, according to survey results released this week by Medscape. The annual survey isn't scientific – and perhaps, not surprising, either -; but it offers insights into what nearly 25,000 physicians earn, and how they view that number.
Fibrex Medical has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany.
A study led by researchers at Center for Infection and Immunity at Columbia University's Mailman School of Public Health and the Department of Medicine at the Columbia University Irving Medical Center reports on the use of a genetic sequencing method to identify viral pathogens behind unexplained respiratory illnesses in Uganda over a five-year period.
An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
› Verified 4 days ago